136.90
price down icon2.89%   -4.08
after-market Handel nachbörslich: 139.19 2.29 +1.67%
loading
Schlusskurs vom Vortag:
$140.98
Offen:
$137.99
24-Stunden-Volumen:
1.67M
Relative Volume:
1.54
Marktkapitalisierung:
$6.88B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
17.09
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
-11.99%
1M Leistung:
-16.68%
6M Leistung:
-28.23%
1J Leistung:
-45.38%
1-Tages-Spanne:
Value
$132.99
$140.15
1-Wochen-Bereich:
Value
$132.99
$153.81
52-Wochen-Spanne:
Value
$132.99
$258.56

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name
Firmenname
Charles River Laboratories International Inc
Name
Telefon
781-222-6000
Name
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Name
Mitarbeiter
20,100
Name
Twitter
@criverlabs
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
CRL's Discussions on Twitter

Vergleichen Sie CRL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
CRL
Charles River Laboratories International Inc
136.90 6.88B 4.06B 413.08M 560.48M 8.01
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
437.91 171.01B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
181.77 134.77B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
393.73 32.47B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
103.00 29.63B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
154.73 28.04B 15.41B 1.37B 2.11B 7.50

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-21 Herabstufung Goldman Buy → Neutral
2025-03-04 Hochstufung Citigroup Sell → Neutral
2025-03-03 Hochstufung Redburn Atlantic Sell → Neutral
2025-01-22 Herabstufung William Blair Outperform → Mkt Perform
2025-01-17 Herabstufung UBS Buy → Neutral
2024-11-18 Herabstufung CLSA Hold → Underperform
2024-11-07 Hochstufung CLSA Underperform → Hold
2024-10-23 Eingeleitet CLSA Underperform
2024-10-14 Eingeleitet Redburn Atlantic Sell
2024-10-07 Herabstufung Evercore ISI Outperform → In-line
2024-10-02 Herabstufung BofA Securities Buy → Neutral
2024-10-01 Herabstufung Citigroup Neutral → Sell
2024-08-08 Herabstufung JP Morgan Overweight → Neutral
2024-08-08 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-28 Herabstufung Argus Buy → Hold
2024-06-07 Eingeleitet Mizuho Neutral
2024-06-06 Eingeleitet Goldman Buy
2024-02-15 Herabstufung Guggenheim Buy → Neutral
2023-09-13 Eingeleitet TD Cowen Market Perform
2023-07-10 Herabstufung Citigroup Buy → Neutral
2023-02-23 Hochstufung Guggenheim Neutral → Buy
2023-01-12 Herabstufung Jefferies Buy → Hold
2022-09-30 Hochstufung Jefferies Hold → Buy
2022-08-25 Eingeleitet Credit Suisse Outperform
2022-08-04 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-05-24 Eingeleitet Guggenheim Neutral
2022-04-25 Herabstufung Jefferies Buy → Hold
2022-04-07 Eingeleitet Stephens Overweight
2022-02-17 Bestätigt BofA Securities Buy
2022-02-17 Hochstufung Citigroup Neutral → Buy
2022-02-17 Bestätigt Deutsche Bank Buy
2022-02-17 Bestätigt Morgan Stanley Overweight
2022-02-17 Bestätigt UBS Buy
2021-08-05 Fortgesetzt Credit Suisse Neutral
2020-12-16 Herabstufung Citigroup Buy → Neutral
2020-09-10 Hochstufung Jefferies Hold → Buy
2020-07-01 Hochstufung BofA Securities Neutral → Buy
2020-05-13 Hochstufung UBS Neutral → Buy
2020-04-21 Herabstufung Jefferies Buy → Hold
2020-03-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-02 Eingeleitet Deutsche Bank Buy
2020-02-18 Hochstufung Wolfe Research Peer Perform → Outperform
2020-01-10 Hochstufung Goldman Neutral → Buy
2020-01-08 Eingeleitet Wells Fargo Overweight
2020-01-07 Eingeleitet Citigroup Buy
2019-10-18 Herabstufung BofA/Merrill Buy → Neutral
2019-06-10 Eingeleitet SVB Leerink Outperform
2019-04-30 Fortgesetzt Evercore ISI Outperform
2018-12-14 Eingeleitet Deutsche Bank Buy
2018-10-09 Eingeleitet UBS Neutral
2018-08-23 Hochstufung Raymond James Mkt Perform → Outperform
2018-07-17 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2018-06-15 Hochstufung KeyBanc Capital Mkts Sector Weight → Overweight
2018-02-14 Hochstufung SunTrust Hold → Buy
Alle ansehen

Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten

pulisher
Apr 03, 2025

How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks? - MSN

Apr 03, 2025
pulisher
Apr 03, 2025

Human Microbiome Sequencing Market Key Players Analysis - openPR.com

Apr 03, 2025
pulisher
Apr 01, 2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Apr 01, 2025
pulisher
Apr 01, 2025

Charles River Integrates Akron Bio’s CSS Line of Liquid Cytokines - Contract Pharma

Apr 01, 2025
pulisher
Mar 31, 2025

Charles River Labs stock hits 52-week low at $150.19 By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate - MSN

Mar 31, 2025
pulisher
Mar 31, 2025

Baird Adjusts Charles River Laboratories International Price Target to $155 From $173, Maintains Neutral Rating - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

Charles River Labs stock hits 52-week low at $150.19 - Investing.com

Mar 31, 2025
pulisher
Mar 31, 2025

Mawer Investment Management Ltd. Buys 5,769 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish? - MSN

Mar 31, 2025
pulisher
Mar 27, 2025

Genetic Toxicology Testing Market To Witness Huge Gains Over - openPR

Mar 27, 2025
pulisher
Mar 27, 2025

Biopharma Layoffs Roundup - Contract Pharma

Mar 27, 2025
pulisher
Mar 26, 2025

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform - BioSpace

Mar 26, 2025
pulisher
Mar 25, 2025

Charles River, Valo Health Identify First Lupus Treatment Candidate Using Logica AI Platform - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire

Mar 25, 2025
pulisher
Mar 24, 2025

Why Charles River Laboratories International, Inc. (CRL) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey

Mar 24, 2025
pulisher
Mar 23, 2025

12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey

Mar 23, 2025
pulisher
Mar 21, 2025

Goldman Sachs Downgrades Charles River Laboratories International (CRL) - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Demystifying Charles River: Insights From 10 Analyst Reviews - Benzinga

Mar 21, 2025
pulisher
Mar 21, 2025

Icon stock, Charles River stock downgraded at Goldman (CRL) - Seeking Alpha

Mar 21, 2025
pulisher
Mar 21, 2025

Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

This FedEx Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga India

Mar 21, 2025
pulisher
Mar 21, 2025

Goldman Sachs cuts Charles River Labs stock rating, target to $170 - Investing.com India

Mar 21, 2025
pulisher
Mar 21, 2025

Goldman Sachs cuts Charles River Labs stock rating, target to $170 By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Goldman Sachs Downgrades Charles River Laboratories International to Neutral From Buy, Adjusts Price Target to $170 From $190 - Marketscreener.com

Mar 21, 2025
pulisher
Mar 20, 2025

Jefferies maintains Charles River Labs stock hold, price target at $169 - Investing.com Canada

Mar 20, 2025
pulisher
Mar 20, 2025

Charles River Laboratories International Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 20, 2025
pulisher
Mar 20, 2025

Interesting CRL Put And Call Options For November 21st - Nasdaq

Mar 20, 2025
pulisher
Mar 19, 2025

Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Mar 19, 2025
pulisher
Mar 18, 2025

Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - Yahoo Finance

Mar 18, 2025
pulisher
Mar 13, 2025

Earnings call transcript: Charles River Labs beats Q4 2024 forecasts By Investing.com - Investing.com UK

Mar 13, 2025
pulisher
Mar 13, 2025

Should You Investigate Charles River Laboratories International, Inc. (NYSE:CRL) At US$171? - Simply Wall St

Mar 13, 2025
pulisher
Mar 11, 2025

Charles River Laboratories to Present at Barclays Global Healthcare Conference - BioSpace

Mar 11, 2025
pulisher
Mar 11, 2025

Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.

Mar 11, 2025
pulisher
Mar 10, 2025

Mutual of America Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World

Mar 10, 2025
pulisher
Mar 09, 2025

Smartleaf Asset Management LLC Increases Position in Charles River Laboratories International, Inc. (NYSE:CRL) - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Fairjourney Biologics acquires Charles River Laboratories South San Francisco facility - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN

Mar 08, 2025
pulisher
Mar 08, 2025

Charles River, LabCorp upgraded, Quest downgraded at Citi on valuation - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

Charles River announces agreement with Singapore General Hospital - SelectScience

Mar 07, 2025
pulisher
Mar 06, 2025

Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Citigroup - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Reasons to Retain Charles River Stock in Your Portfolio for Now - Yahoo Finance

Mar 06, 2025
pulisher
Mar 05, 2025

Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire Inc.

Mar 05, 2025
pulisher
Mar 04, 2025

Charles River Laboratories Shares Rise After Citigroup Upgrade -March 04, 2025 at 02:53 pm EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Citi raises Charles River stock rating, lifts target to $175 - Investing.com

Mar 04, 2025

Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$133.87
price down icon 3.49%
diagnostics_research DGX
$164.18
price down icon 3.78%
diagnostics_research LH
$225.00
price down icon 3.62%
diagnostics_research WAT
$324.92
price down icon 5.85%
diagnostics_research MTD
$1,022.66
price down icon 6.63%
diagnostics_research IQV
$154.73
price down icon 7.73%
Kapitalisierung:     |  Volumen (24h):